Halofantrine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for halofantrine hydrochloride and what is the scope of patent protection?
Halofantrine hydrochloride
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for halofantrine hydrochloride
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 7 |
Patent Applications: | 564 |
Formulation / Manufacturing: | see details |
DailyMed Link: | halofantrine hydrochloride at DailyMed |
Recent Clinical Trials for halofantrine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Walter and Eliza Hall Institute of Medical Research | Phase 3 |
Papua New Guinea Institute of Medical Research | Phase 3 |
Lihir Medical Centre | Phase 3 |
US Patents and Regulatory Information for halofantrine hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | HALFAN | halofantrine hydrochloride | TABLET;ORAL | 020250-001 | Jul 24, 1992 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |